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available. Several topical preparations are
approved for the treatment of tinea cruris.
Selection should be based on patient com-
pliance (duration of treatment), overall
cost, and tolerability. The 2 main classes of
antifungals are allylamines and azoles.
Allylamines. Allylamines offer a shorter
duration of therapy, lower relapse rates,
and work independent of the cytochrome
P450 system. Multiple RCTs have docu-
mented the efficacy and safety of the 2
available allylamine antifungals, terbinafine
and naftifine, when compared with placebo
and various azoles. 
Terbinafine is available in several 1%
formulations (emulsion-gel, cream, and
solution/spray), all studied and dosed once
daily for 1 week. One placebo controlled
■ Evidence summary
Tinea cruris (“jock itch”) is a superficial
dermatophyte infection of the groin and
surrounding skin. Obese adult men are
affected more than women, and it is rarely
seen in children. Because excessive perspi-
ration is the most common predisposing
factor, patient education on proper
hygiene makes intuitive sense for success-
ful treatment, yet it has not been studied.1
Trichophyton rubrum is the most common
source of tinea cruris, as well as tinea cor-
poris (“ringworm”), in the United States.2
Most studies involving patients with tinea
cruris combine data with tinea corporis.
Although more than 25 RCTs docu-
ment the safety and efficacy of antifungal
treatments, few head-to-head trials are
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After clinical diagnosis and microscopic 
confirmation, tinea cruris is best treated with a 
topical allylamine or an azole antifungal (strength
of recommendation: A, based on multiple random-
ized controlled trials [RCTs]). Differences in current
comparison data are insufficient to stratify the 2
groups of topical antifungals. Determining which
group to use depends on patient compliance, 
medication accessibility, and cost. The fungicidal
allylamines (naftifine and terbinafine) and bute-
nafine (allylamine derivative) are a more costly
group of topical tinea treatments, yet they are
more convenient as they allow for a shorter 
duration of treatment compared with fungistatic
azoles (clotrimazole, econazole, ketoconazole, 
oxiconazole, miconazole, and sulconazole). 
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Choice of treatment should reflect cost 
and convenience to the patient
This review illustrates that the “best way” to 
treat a problem can have more to do with the
needs of a given patient than intrinsic differences
between treatments. All reviewed treatments were
roughly therapeutically equivalent and equally
safe. This leaves the choice of treatment to 
reflect the importance of cost and convenience 
to the patient. If cost is an issue for the patient, 
the frugal way to treat tinea cruris is to have the
patient go to the vaginitis treatment section of the
pharmacy and pick up a 15-g tube of miconazole
or clotrimazole cream for $7 to $10. Terbinafine
cream or spray costs $10 to $13 over the counter,
but it reduces the onus of compliance to 
once-a-day for 1 week. If terbinafine 1% solution 
is preferred, a 30-mL bottle costs $77. Most 
of the time, I let the patient make their 
own choice. 
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trial showed the 1% emulsion-gel version
(Lamisil) was effective in 89% of the study
population vs 23% of the placebo group
(NNT=1.5); it was particularly suitable on
hairy skin. Seven weeks post-treatment,
84% of the intent-to-treat population of the
Lamisil group remained mycologically neg-
ative.3 Data combined from 2 other RCTs
yielded 83% efficacy 3 weeks post-treat-
ment when 66 patients were treated with
terbinafine 1% cream, compared with 12%
efficacy for 73 patients using the vehicle
cream (NNT=1.4).4 Another placebo-con-
trolled study of 66 patients demonstrated
100% microscopic cure of terbinafine 1%
solution by week 2 and maintaining 90%
cure at 4 weeks.5
In a multicenter, double-blind RCT
funded by the manufacturers of terbinafine,
bifonazole 1% cream for 3 weeks was
compared with terbinafine 1% cream used
daily for 1 week (followed by 2 weeks of its
vehicle cream). Mycological and clinical
cure rates were greater than 95% in both
groups at 3 weeks. At the 8-week follow-
up, no statistically significant differences
were seen in KOH positivity rates (20.24%
of patients in the bifonazole-treated group
were KOH-positive vs 11.76% in the
terbinafine group). Symptom relapse rates
at 8 weeks were not available.6
In a 4-week study involving 104 patients,
naftifine 1% cream (Naftin) was compared
with econazole 1% cream (Spectazole) (both
applied twice daily). At the end of the study,
naftifine 1% cream had a higher (but not sta-
tistically significant) mycological and clinical
cure rate of 78% compared with 68% with
econazole 1% cream.7 Similar results (79%
mycological cure) were seen in a placebo-con-
trolled trial with 70 patients using once daily
naftifine 1% cream after 2 weeks of treat-
ment (NNT=2).8
Butenafine (Mentax), a benzylamine
antifungal, was 88% to 93% mycologically
effective in a noncomparative study, when
used twice daily for 2 weeks.9 Similar results
were found in a study of 76 patients with
tinea cruris; after 2 weeks of daily applica-
tion, 78% (modified intent-to-treat group)
were mycologically cured. Mycological cure
plus “cleared” or “excellent” clinical evalu-
ation remained for 73% at day 42 vs 5% of
the placebo group (NNT=1.47).10
Azoles. Azoles are less expensive than
allylamines, but require longer treatment
periods, theoretically compromising patient
adherence to therapy. One of the more pop-
ular azoles is clotrimazole (Lotrimin,
Mycelex), one of the oldest antifungal
treatments. One RCT compared cure rates
for 139 patients for clotrimazole 1% cream
compared with ciclopirox olamine 1%
cream when both were applied twice daily
for 28 days. By the end of the 4-week peri-
od, 69% of the clotrimazole group was
clinically and mycologically cured com-
pared with 64% of the ciclopirox group.11
Miconazole 2% cream (Micatin,
Monistat) (used twice daily for 2 weeks by
inmates in a Florida prison) demonstrated
75.5% clinical clearing (against tinea cruris,
pedis, or corporis, or Candida cutaneous
infections) when compared with placebo
(NNT=1.57). Of the 99 patients evaluated,
48 were diagnosed with tinea cruris; howev-
er, results were not broken down into diag-
nostic category. The length of follow-up for
these patients was not disclosed.12
Alternative therapy. Ajoene 0.6% gel
(isolated from garlic), was as effective as
terbinafine 1% cream (both applied twice
daily for 2 weeks) in a RCT of 60
Venezuelan Army soldiers.13 Sixty days
after treatment, 73% of the Ajoene-treated
patients and 71% in the terbinafine group
were asymptomatic. An open-pilot study of
14 patients with tinea cruris demonstrated
71% mycological cure with a honey, olive
oil, and beeswax (1:1:1) mixture, applied 3
times daily up to 3 weeks, likely due to
honey’s inhibitory effect on fungus and
beeswax’s anti-inflammatory properties.14
Recommendations from others
The Sanford Guide to Antimicrobial
Therapy (2005) recommends topical bute-
nafine and terbinafine as primary agents of
choice for tinea cruris due to their fungi-
cidal activity.15 The American Academy of
Family Physicians recommends any of the
topical antifungal treatments as first-line
Use of an 
allylamine or azole
antifungal depends
on patient 
compliance and
cost—allylamines
are more costly 
but allow for 
shorter treatments
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treatment for tinea cruris.16 A systematic
review on tinea pedis topical therapy
acknowledges the higher cure rates by ally-
lamines, compared with azoles, but con-
cludes that azoles remain the most cost-
effective in the treatment of tinea pedis.
17
No recent guidelines from the American
Academy of Dermatology are available.
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abdomen), of which GERD is a subset.6
The guidelines recommend gastroenterolo-
gy consultation or upper endoscopy to rule
out neoplastic or pre-neoplastic lesions if
alarm symptoms (TABLE) suggesting com-
plicated GERD are present.7
The Institute for Clinical Systems
Improvement guidelines on dyspepsia and
GERD recommend that all patients aged
≥50 years with symptoms of uncomplicat-
ed dyspepsia undergo upper endoscopy
non-urgently because of the increased inci-
dence of peptic ulcer disease, pre-neoplastic
lesions, malignancy, and increased morbid-
ity out of proportion to symptoms that are
more common in an older patient popula-
tion. The guidelines also recommend
endoscopy for patients aged ≥50 years with
uncomplicated GERD and the presence of
symptoms for greater than 10 years
because of the increased risk of pre-
neoplastic and neoplastic lesions, including
Barrett’s esophagus.8
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